TAE Life Sciences Takes Center Stage at PTCOG: Co-Hosting BNCT Symposium and Unveiling Groundbreaking Small Molecule Drug Development for BNCT
MADRID and IRVINE, Calif., June 9, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneering company in the field of cancer treatment, announces its participation in the 61st annual Particle Therapy Co-Operative Group (PTCOG) conference in Madrid, Spain. The event, held from June 10 – 16, 2023, will bring together leading experts, researchers, and organizations dedicated to advancing particle therapy in cancer treatment. TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).
- TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).
- Morrison will discuss the breakthrough work conducted by TAE Life Sciences in developing targeted boronated small molecule drugs as alternatives to 4-boronophenylalanine (BPA).
- TAE Life Sciences will also have a poster presentation at PTCOG showcasing the technical details of its tandem-architecture neutron beam system for BNCT cancer treatment.
- TAE Life Sciences invites conference attendees and media representatives to attend Tuesday evening's symposium to learn more about the latest BNCT device and drug innovations and breakthroughs.